File Download
  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): an Asia-Pacific nonrandomized phase II study (APEC)

TitleEfficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): an Asia-Pacific nonrandomized phase II study (APEC)
Authors
KeywordsMedical sciences
Oncology medical sciences
Radiology and nuclear medicine pharmacy and pharmacology biology
Cytology and histology
Issue Date2013
PublisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/
Citation
The 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 31 May-4 June 2013. In Journal of Clinical Oncology, 2013, v. 31 n. 15 suppl., abstract no. e14501 How to Cite?
AbstractBACKGROUND: Randomized studies have shown that weekly cetuximab added to first-line FOLFOX or FOLFIRI improves clinical outcome in patients (pts) with KRAS wild-type (wt) mCRC. This Asia-Pacific multicenter study investigated FOLFOX or FOLFIRI + every 2 weeks cetuximab (C) as first-line therapy in pts with KRAS wt mCRC ...
DescriptionThis abstract will not be presented at the 2013 ASCO Annual Meeting but has been published in conjunction with the meeting.
Open Access Journal
Persistent Identifierhttp://hdl.handle.net/10722/186974
ISSN
2015 Impact Factor: 20.982
2015 SCImago Journal Rankings: 9.204

 

DC FieldValueLanguage
dc.contributor.authorCheng, ALen_US
dc.contributor.authorCornelio, GHen_US
dc.contributor.authorShen, Len_US
dc.contributor.authorPrice, TJen_US
dc.contributor.authorYang, TSen_US
dc.contributor.authorChung, IJen_US
dc.contributor.authorDai, Gen_US
dc.contributor.authorLin, JKen_US
dc.contributor.authorSharma, Aen_US
dc.contributor.authorYeh, KHen_US
dc.contributor.authorMa, Ben_US
dc.contributor.authorZaatar, Aen_US
dc.contributor.authorGuan, ZZen_US
dc.contributor.authorMasood, Nen_US
dc.contributor.authorSrimuninnimit, Ven_US
dc.contributor.authorYau, TCCen_US
dc.contributor.authorSarholz, Ben_US
dc.contributor.authorLim, RSCen_US
dc.date.accessioned2013-08-20T12:26:29Z-
dc.date.available2013-08-20T12:26:29Z-
dc.date.issued2013en_US
dc.identifier.citationThe 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL., 31 May-4 June 2013. In Journal of Clinical Oncology, 2013, v. 31 n. 15 suppl., abstract no. e14501en_US
dc.identifier.issn0732-183X-
dc.identifier.urihttp://hdl.handle.net/10722/186974-
dc.descriptionThis abstract will not be presented at the 2013 ASCO Annual Meeting but has been published in conjunction with the meeting.-
dc.descriptionOpen Access Journal-
dc.description.abstractBACKGROUND: Randomized studies have shown that weekly cetuximab added to first-line FOLFOX or FOLFIRI improves clinical outcome in patients (pts) with KRAS wild-type (wt) mCRC. This Asia-Pacific multicenter study investigated FOLFOX or FOLFIRI + every 2 weeks cetuximab (C) as first-line therapy in pts with KRAS wt mCRC ...-
dc.languageengen_US
dc.publisherAmerican Society of Clinical Oncology. The Journal's web site is located at http://www.jco.org/-
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectRadiology and nuclear medicine pharmacy and pharmacology biology-
dc.subjectCytology and histology-
dc.titleEfficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): an Asia-Pacific nonrandomized phase II study (APEC)en_US
dc.typeConference_Paperen_US
dc.identifier.emailYau, TCC: tyaucc@hku.hken_US
dc.identifier.authorityYau, TCC=rp01466en_US
dc.description.naturelink_to_OA_fulltext-
dc.identifier.hkuros217111en_US
dc.identifier.volume31en_US
dc.identifier.issue15 suppl.-
dc.publisher.placeUnited States-
dc.customcontrol.immutablesml 131016-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats